Business Wire

The European Joint Programming Initiative on Neurodegenerative Disease Research (JPND) Organises Its International Scientific Meeting

26.11.2019 20:37:00 EET | Business Wire | Press release

Share

To disseminate up-to-date research achievements from 51 completed JPND-supported projects3 to relevant stakeholders, liaise, exchange knowledge and network, projects coordinators and their research consortiums, leading researchers and stakeholders will meet at the Royal Flemish Academy of Belgium for Sciences and the Arts in Brussels, Belgium, for a two-day symposium from 27 November to 28 November, 2019. This promises to provide a unique platform and opportunity for researchers to find out about one another’s work, communicate their latest research findings from their completed projects, build new relationships and enhance existing ones.

JPND Chair, Professor Philippe Amouyel says: “As the first and largest global collaborative research initiative established to tackle the growing challenge posed by neurodegenerative diseases, JPND’s ultimate goal is to improve the scientific understanding of neurodegenerative diseases, provide innovative approaches for their prevention, diagnosis and treatment, and ensure that individuals receive optimal care and quality of life at all stages of their illness. This symposium aims to facilitate knowledge sharing and communication between the different research groups and to disseminate up-to-date research achievements to relevant stakeholders.”

Project topics to be presented will range from Alzheimer’s to Parkinson’s diseases to rarer diseases such as Huntington’s disease, Amyotrophic Lateral Sclerosis, Prion disease, Spinal Muscular Atrophy and Spinocerebellar Ataxia .

Apart from 12 scientific sessions chaired and moderated by leading researchers in the field of neurodegenerative disease, the symposium will also delve into major questions of research via four thematic workshops, namely: Patient and Public Involvement in Research, Interactions with Industry, Knowledge Dissemination and Data Sharing.

Note to Editors:

JPND is committed to aligning and building upon national programmes to increase impact and effectiveness of research and to identify common goals that would benefit from joint action.

  • The origins and progression of neurodegenerative diseases
  • Disease mechanisms and models
  • Diagnosis, prognosis and disease definitions
  • Developing therapies, preventive strategies and interventions
  • Health and social care

JPND receives support from the European Commission.

Web: www.jpnd.eu
Twitter: @JPNDEurope
LinkedIn: https://www.linkedin.com/company/jpnd-joint-programme-neurodegenerative-disease-research

1 The EU Joint Programme – Neurodegenerative Disease Research (JPND) is the largest global research initiative aimed at tackling the challenge of neurodegenerative diseases. JPND aims to increase coordinated investment between participating countries in research aimed at finding causes, developing cures, and identifying appropriate ways to care for those with neurodegenerative diseases.
2 In 2015, JPND launched a joint transnational co-funded call in partnership with the European Commission under the ERA-NET Co-fund scheme in three JPND priority areas: Longitudinal Cohort Approaches, Advanced Experimental Models and Risk and Protective Factors
3 Research projects supported by the JPND calls of 2011 to 2013 and the JPco-fuND call of 2015

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press
Name: Karin YEO
Mobile: +33 07 8227 2887
Email: karin.yeo@jpnd.eu

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

INSEAD Launches Immersive AI Cases as Its AI-Powered Learning Portfolio Passes 40 Experiences17.9.2026 12:00:00 EEST | Press release

INSEAD, The Business School for the World, today announced two milestones inAI-enabled learning: the commercial launch of its firstImmersive AI Cases via INSEAD Publishing and the expansion of its Immersive Learning portfolio to reach over 40 AI-powered learning experiences in the INSEAD classroom. Together, these developments mark an important milestone in INSEAD’s vision to translate AI-enabled learning into scalable educational offerings for educators and learners worldwide. They also demonstrate the growing adoption of immersive learning across the school and represent a key step in advancing the ambitions of IN:AI, INSEAD’s initiative to harness AI to transform business education and prepare leaders for an AI-enabled world. Francisco Veloso, Dean of INSEAD, said: “The future of management education will not be about choosing between human expertise and AI, but about bringing the two together in ways that deepen learning and strengthen judgement. We are putting this principle into

LTM Honoured with Avasant Digital Masters Award 202617.9.2026 12:00:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced that it has been recognized with the Digital Masters Award 2026 in the Innovator category by Avasant, a leading management consulting firm. The award recognizes LTM's commitment to innovation, excellence, and its ability to drive transformative business outcomes for clients through its portfolio of AI-powered offerings. The award was presented during the Digital Masters Awards Ceremony at Partner Connect 2026 in Los Angeles. LTM was among the 18 service providers shortlisted from a field of over 76 global technology service providers assessed by Avasant for this year's Digital Masters Awards. This recognition reflects LTM's strong leadership, domain expertise, and continued contribution to delivering exceptional value for clients globally. "This recognition reflects our focus on helping clients leverage AI to accelerate transformation, create measurable business value, and stay ahead in a rapidly e

IQM to Deliver Its First Quantum Computer in South America to Brazil’s Eldorado Research Institute17.9.2026 10:43:00 EEST | Press release

IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced a purchase agreement with the Eldorado Research Institute to deploy its first quantum computer in South America, marking IQM's entry into the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917582765/en/ IQM to deliver its first quantum computer in South America to Brazil’s Eldorado Research Institute The IQM Spark quantum computer will be installed at Eldorado's Campinas headquarters, about 100km northwest of São Paulo, in the first quarter of 2027, giving researchers, engineers, universities and industry partners direct access to quantum computers. The agreement also includes remote access to IQM's 54-qubit cloud-based system in Europe, allowing Brazilian teams to develop applications on hardware they own and then move to larger-scale quantum workloads when a problem requires it. “Brazil has the talent, the

Merz Therapeutics Receives EU/EEA Approval for XEOMIN® for the Treatment of Pediatric Spasticity Associated With Pes Equinus17.9.2026 09:00:00 EEST | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has received approval in the European Union (EU) / European Economic Area (EEA) for XEOMIN® (incobotulinumtoxinA) for the symptomatic treatment of spasticity associated with pes equinus, a condition in which tight calf muscles cause the foot to point downward, in ambulant and non-ambulant children and adolescents with cerebral palsy (CP) aged 2 to 17 years.1,2 This approval expands access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often disruptive symptom in children and adolescents with neurological conditions, including CP. This condition is associated with muscle tightness that can severely restrict physical movement, daily functioning, and personal autonomy. Among children and youth, CP stands as a primary driver of this symptom and remains the most prevalent childhood motor disability,

Mediterranean Network for Haemoglobinopathies Launches in Rome, Connecting Clinical Experts and Patient Leaders to Advance Equitable Care17.9.2026 09:00:00 EEST | Press release

The Mediterranean Network for Haemoglobinopathies (MNfH) was recently launched at Palazzo Wedekind in Rome, bringing together leading clinicians and patient representatives from Cyprus, Greece, and Italy, with the Thalassaemia International Federation (TIF). Supported by Avanzanite Bioscience as Founding Sponsor, the independent regional platform will connect expertise across borders, strengthen the patient voice, and turn shared knowledge into practical initiatives that can improve care for people living with haemoglobinopathies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916107487/en/ Adam Plich, Co-Founder and CEO, Avanzanite Bioscience. Avanzanite enabled the establishment of the Network in recognition of both the considerable expertise that already exists across the Mediterranean and the persistent gaps that remain in access to specialist care, sustainable blood supplies, treatment advances and evidence-based inn

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye